Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

DEFINITIVE HEALTHCARE CORP.

(DH)
  Report
Delayed Nasdaq  -  01:00 2022-11-25 pm EST
11.10 USD   +1.19%
11/07Goldman Sachs Cuts Price Target on Definitive Healthcare to $17 From $31, Maintains Neutral Rating
MT
11/07Deutsche Bank Adjusts Definitive Healthcare Price Target to $14 From $26, Maintains Hold Rating
MT
11/04Needham Adjusts Price Target on Definitive Healthcare to $15 From $32, Maintains Buy Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Days
:
Hours
:
Minutes
:
Seconds

Definitive Healthcare : Announces Timing of Its Third Quarter 2021 Financial Results Conference Call and Webcast

10/20/2021 | 04:06pm EST

FRAMINGHAM, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that its third quarter ended September 30, 2021 financial results will be released on Monday, November 8, 2021, after market close. The company will host a conference call and webcast at 5:00 PM (ET) / 2:00 PM (PT) to discuss the company’s financial results.

A live audio webcast of the event will be available on the Definitive Healthcare’s Investor Relations website at https://ir.definitivehc.com/.

A live dial-in will be available at (877) 407-3982 (domestic) or (201) 493-6780 (international). The conference ID number is 13723517. Shortly after the conclusion of the call, a replay of this conference call will be available through November 22, 2021 at (844) 512-2921 (domestic) or (412) 317-6671 (international). The replay passcode is 13723517.

About Definitive Healthcare
At Definitive Healthcare, our passion is to transform data, analytics and expertise into healthcare commercial intelligence. We help clients uncover the right markets, opportunities and people, so they can shape tomorrow’s healthcare industry. Our SaaS platform creates new paths to commercial success in the healthcare market, so companies can identify where to go next.

Media:
Danielle Johns
djohns@definitivehc.com

Investor Relations:
Brian Denyeau
brian.denyeau@icrinc.com

Source: Definitive Healthcare Corp.


Primary Logo

Source: Definitive Healthcare Corp.

2021 GlobeNewswire, Inc., source Press Releases

All news about DEFINITIVE HEALTHCARE CORP.
11/07Goldman Sachs Cuts Price Target on Definitive Healthcare to $17 From $31, Maintains Neu..
MT
11/07Deutsche Bank Adjusts Definitive Healthcare Price Target to $14 From $26, Maintains Hol..
MT
11/04Needham Adjusts Price Target on Definitive Healthcare to $15 From $32, Maintains Buy Ra..
MT
11/04Credit Suisse Cuts Definitive Healthcare's PT to $19 From $24, Says Macro Continues to ..
MT
11/04Morgan Stanley Adjusts Price Target on Definitive Healthcare to $21 From $23, Maintains..
MT
11/03Definitive Healthcare Seeks M&A
CI
11/03Transcript : Definitive Healthcare Corp., Q3 2022 Earnings Call, Nov 03, 2022
CI
11/03DEFINITIVE HEALTHCARE CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIO..
AQ
11/03Definitive Healthcare Corp. Reports Earnings Results for the Third Quarter and Nine Mon..
CI
11/03Definitive Healthcare Corp. : Results of Operations and Financial Condition, Change in Dir..
AQ
More news
Analyst Recommendations on DEFINITIVE HEALTHCARE CORP.
More recommendations
Financials (USD)
Sales 2022 221 M - -
Net income 2022 -37,1 M - -
Net cash 2022 30,5 M - -
P/E ratio 2022 -34,5x
Yield 2022 -
Capitalization 1 166 M 1 166 M -
EV / Sales 2022 5,15x
EV / Sales 2023 4,05x
Nbr of Employees 676
Free-Float 65,9%
Chart DEFINITIVE HEALTHCARE CORP.
Duration : Period :
Definitive Healthcare Corp. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DEFINITIVE HEALTHCARE CORP.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Last Close Price 11,10 $
Average target price 17,82 $
Spread / Average Target 60,5%
EPS Revisions
Managers and Directors
Robert Musslewhite Chief Executive Officer & Director
Jonathan Maack President
Richard Douglas Booth Chief Financial Officer
Jason Krantz Executive Chairman
Scott Oberlink Chief Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
DEFINITIVE HEALTHCARE CORP.-59.39%1 166
MICROSOFT CORPORATION-26.41%1 844 908
SYNOPSYS INC.-9.73%50 864
DASSAULT SYSTÈMES SE-30.63%49 598
CADENCE DESIGN SYSTEMS, INC.-10.22%45 896
ATLASSIAN CORPORATION-67.44%31 718